News: UCB S.A. (UCB.BR)

UCB.BR on Brussels Stock Exchange

44.44EUR
17 May 2013
Price Change (% chg)

€-0.55 (-1.21%)
Prev Close
€44.99
Open
€44.96
Day's High
€45.08
Day's Low
€44.35
Volume
224,554
Avg. Vol
311,629
52-wk High
€50.24
52-wk Low
€36.35

Search Stocks
Select another date:

Thu, Apr 25 2013

UCB suffers as cold weather delays hay fever season

BRUSSELS, April 25 - Belgian drugmaker UCB had a difficult first quarter as cold spring weather in Europe meant fewer hay fever sufferers were buying its allergy medicines, it said on Thursday.

Continue Reading

UCB reaches maximum 250 mln euros with retail bond sale

BRUSSELS, March 27 - Belgium-based drugmaker UCB said it has raised the maximum 250 million euros ($321.47 million) it was aiming for by selling a retail bond on the Brussels stock exchange to help refinance its debt.

BRIEF-UCB, Five Prime Therapeutics collaborate

BRUSSELS, March 19 - UCB S.A. : * UCB and Five Prime Therapeutics announce strategic discovery

UCB says had positive trial for Vimpat as monotherapy

BRUSSELS - Belgian pharmaceutical company UCB said on Tuesday its new epilepsy treatment Vimpat had produced promising results in a Phase III trial into its use without other drugs.

UCB gets Japan clearance for two new drugs

BRUSSELS - Belgian pharmaceutical company UCB has secured two regulatory clearances in Japan, further cementing its worldwide shift to a new generation of drugs.

TEXT-S&P assigns 'A-' rating to l'Union Canadienne

Overview -- L'Union Canadienne (UC) is a Quebec-based property-casualty insurer. -- UC is considered strategically important to Royal & SunAlliance's (RSA) Canadian operations, which acquired UC on Oct. 1, 2012. -- UC's credit profile is also supported by good competitive position, good operating performance, and adequate capitalization. -- We are assigning our 'A-' financial strength and counterparty credit ratings to UC; the outlook is stable. Rating Action On Dec. 19,

Select another date:

Press Releases

Search Stocks